Ameritas Advisory Services’s Syndax Pharmaceuticals SNDX Stock Holding History

Ameritas Advisory Services’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87	Buy	+4	New	+$83	﹤0.01%	1915

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Ameritas Advisory Services's SNDX Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 4 shares worth $87. The stake represents ﹤0.01% of the portfolio and ranks #1915 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Ameritas Advisory Services held 4 shares of Syndax Pharmaceuticals worth $87 as of Q2 2026.
Syndax Pharmaceuticals was a new Ameritas Advisory Services position in Q2 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1915 holding.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.